SCHEMBL7715844

SCHEMBL7715844

CCOC(=O)c1ccc(O)c(OCC)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.77
CA12 O43570 4/20 0.70
CA1 P00915 4/20 0.70
CA2 P00918 4/20 0.70
CA7 P43166 4/20 0.70
CA9 Q16790 4/20 0.70
CA14 Q9ULX7 4/20 0.70
KDM4E B2RXH2 2/20 0.59
POLB P06746 1/20 0.59
ESR1 P03372 1/20 0.56
ESR2 Q92731 1/20 0.56
HDAC6 Q9UBN7 1/20 0.55
LMNA P02545 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
MAOA P21397 1/20 0.54
ALDH1A1 P00352 2/20 0.53
MEN1 O00255 1/20 0.52
MAPT P10636 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8889070 0.89 KDM4E (0.76) HSD17B2CA12CA1CA2CA7
SCHEMBL1990526 0.87 CA12 (0.70) HSD17B2CA12CA1CA2CA7
SCHEMBL3573863 0.87 HSD17B2 (0.62) HSD17B2CA12CA1CA2CA7
SCHEMBL155638 0.87 HSD17B2 (1.00) HSD17B2CA12CA1CA2CA7
SCHEMBL17040238 0.86 HSD17B2 (0.67) HSD17B2CA12CA1CA2CA7
SCHEMBL6580057 0.86 HSD17B2 (0.67) HSD17B2CA12CA1CA2CA7
SCHEMBL8887069 0.86 ESR1 (0.66) HSD17B2CA12CA1CA2CA7
SCHEMBL27683302 0.86 HSD17B2 (0.67) HSD17B2CA12CA1CA2CA7
SCHEMBL1011945 0.86 HSD17B2 (0.61) HSD17B2CA12CA1CA2CA7
SCHEMBL1561197 0.86 CA12 (0.79) HSD17B2CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5686406-A Vanillic acid ester perfuming agents RHONE-POULENC CHIMIE (FR) 1997-11-11 US claimed
US-6376512-B1 FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-23 US disclosed
US-5686406-A Vanillic acid ester perfuming agents RHONE-POULENC CHIMIE (FR) 1997-11-11 US disclosed
EP-0315399-B1 Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same RHONE POULENC RORER INT (US) 1996-01-10 EP disclosed
US-5059610-A QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1991-10-22 US disclosed
US-4920132-A Quinoline derivatives and use thereof as antagonists of leukotriene D4 RORER PHARMACEUTICAL CORP. (US) 1990-04-24 US disclosed